Sacubitril is primarily used in combination with valsartan as a treatment for heart failure, specifically for patients with reduced ejection fraction (HFrEF). This combination, known as sacubitril/valsartan, works by inhibiting neprilysin and blocking the angiotensin II receptor, which helps to relax blood vessels, reduce sodium retention, and decrease the strain on the heart. It is often prescribed to improve symptoms, enhance quality of life, and reduce the risk of hospitalization and cardiovascular death in patients with chronic heart failure. The therapy is typically recommended for patients who remain symptomatic despite standard treatments like ACE inhibitors or beta-blockers. Regular monitoring of kidney function and potassium levels is essential during its use to manage potential side effects.